“BRAF, microsatellite instability (MSI), KRAS and NRAS molecular tumor marker testing are critical today for immunotherapy treatment decisions in colon cancer.” “The colon cancer cells that survived chemotherapy may not be the same as the cells who died.” Liquid biopsy can monitor in real time “molecular escape” of colorectal tumor.
Transcript of video
Colon cancer immunotherapy. What is Molecular escape of colon cancer tumor? Colorectal cancer patients with microsatellite instability (MSI) are sensitive to immune modulator medications. BRAF, microsatellite instability (MSI), KRAS and NRAS molecular tumor marker testing are necessary for immunotherapy treatment decisions in colon cancer. Leading German-American colorectal cancer oncologist discusses colon cancer immunotherapy progress. Colon cancer tumor mutations change with time during treatment. This is molecular escape of tumor from chemotherapy medications effects. Tumor marker profiling must be done during treatment repeatedly to match patients with the correct targeted immunotherapy medications. Colorectal cancer targeted immunotherapy and chemotherapy options. Advanced stage 4 colon cancer treatment by targeted immunotherapy. Medical second opinion confirms colorectal cancer diagnosis at genetic level. Medical second opinion also confirms colon cancer cure is possible in metastatic colon cancer. Best precision medicine treatment for advanced stage 4 colon cancer with metastatic lesions. Medical second opinion helps to select a personalized medicine targeted treatment for stage 4 colorectal cancer. Get medical second opinion on advanced colorectal cancer. Be confident that your targeted BRAF, KRAS EGFR or immunotherapy treatment is the best. Best colorectal cancer treatment by new immunotherapy, immune checkpoints inhibitor medications and multikinase inhibitors. Video interview with leading expert in metastatic colorectal cancer treatment from California. Colon cancer immunotherapy. Molecular escape of colon cancer tumor. BRAF, KRAS, NRAS, MSI tumor markers. Dr. Heinz-Josef Lenz, MD (Colorectal Cancer Expert, California). We already talked about the new immunotherapies available to treat metastatic colon cancer. They target the immune system checkpoints in metastatic colon cancer tumors. Immune modulators in metastatic colon cancer are not as effective as in melanoma and non-small cell lung cancer. But we need to select those metastatic colon cancer patients out who are very sensitive to immune modulator medications. This patient population is usually characterized by a status of microsatellite instability (MSI) of their colon cancer tumor. BRAF, microsatellite instability (MSI), KRAS and NRAS molecular tumor marker testing are absolutely critical today for immunotherapy treatment decisions in colon cancer. These molecular markers (BRAF, MSI, KRAS, NRAS) are particularly important. We should consider new colon cancer immunotherapy treatment regimens. They are usually not part of the standard treatment protocols that we offer to patients with colon cancer. But we have to go beyond that decisions. There are very often mutations in cancer that are potentially be “treatable”. The question is how often do we find mutations in patients with metastatic colon cancer? Some of these colon cancer tumor mutations may be found only in 1% or 2% of patients with colon cancer. Should we test for these mutations in order to be ready for subsequent immunotherapy treatments? There is discussion among doctors about integration of the additional genetic testing in our clinical practice. Colorectal cancer oncologists lead precision medicine. Dr. Heinz-Josef Lenz, MD (Colorectal Cancer Expert, California). But there has been an incredible revolution of thinking about molecular testing in colon cancer. That is very important for everyone to know. Because when we have a diagnosis of colon cancer, we do the molecular testing of colon cancer tumor. We find certain mutations, and then we treat patient with colon cancer correctly. Colon cancer tumor cells who survive are not the same cells who die. Over time, these colon cancer tumor cells thato survive may be not the same. They are not same cells we tested as a majority of the cells at the time of diagnosis of colon cancer. Dr. Anton Titov, MD. It’s also an issue of temporal profiling of the colon cancer tumor in evolution. Cancer treatment is adjusted to the evolving colon cancer tumor or remaining tumor cells. Dr. Heinz-Josef Lenz, MD (Colorectal Cancer Expert, California). Yes, and people call that “molecular escape.” The colon cancer cells who survived may now be the same as the cells who die. Colon cancer cells who survive have a mechanism to really fight off the treatment of colon cancer. Dr. Heinz-Josef Lenz, MD (Colorectal Cancer Expert, California). How do we monitor evolution of colon cancer tumor cells in time? How can we go back to the colon cancer tumor as the treatment progresses? Do we need to biopsy the colon cancer tumor again? It could be an invasive procedure. It depends where the tumor is located. There has been an incredible new technology. It is called liquid biopsy. See next interview segment. Colon cancer immunotherapy works in 5-10% patients. BRAF and MSI mutations predict immunotherapy success in colon cancer. Molecular escape of tumor is important to consider.